Full-Time

Machine Learning Engineer/Applied Scientist

Search & Recommendations

Posted on 7/15/2024

Biorender

Biorender

201-500 employees

Online platform for creating scientific illustrations

No salary listed

Senior, Expert

Remote in Canada

Remote-first with flexibility to work from anywhere in Canada.

Category
Applied Machine Learning
Deep Learning
Natural Language Processing (NLP)
AI & Machine Learning
Required Skills
Agile
Python
Tensorflow
Data Structures & Algorithms
Pytorch
Java
Elasticsearch
Scala
Natural Language Processing (NLP)
Requirements
  • Extensive industry experience as an ML engineer with expert level knowledge in one or more areas: Information Retrieval, Recommender Systems, Learning-to-Rank, Large Language Models, NLP, Deep Learning, Transfer Learning, Multi-task Learning, Graph Neural Network, Human-in-the-loop or similar
  • Hands-on experience with both traditional keyword-based search technologies as well as modern search paradigm utilizing vector-based retrieval algorithms and search systems such as Elasticsearch
  • Experience with deep learning frameworks such as PyTorch and TensorFlow, Large Language Models, Generative AI, Langchain, Transformer models or related
  • Experience with data exploration, analysis, and feature engineering
  • Excellent programming skills with one or more of the following languages python, scala, java
  • Expertise with operationalizing, monitoring, and scaling machine learning models and pipelines in cloud ecosystems
  • Previous experience working cross-functionally with product and engineers to deliver solutions with complex requirements in an agile environment
  • You have experience building a variety of ML applications end to end
  • Familiar with the state-of-the-art deep learning and AI research
  • Experience with distributed model training
  • Experience developing custom model architectures
Responsibilities
  • Design and execute multi-quarter ML initiatives that deliver measurable technical, organizational, or business impacts in our Search & Recommendations domain.
  • Oversee the performance and continued optimization of our search engine and recommendation systems: build machine learning models to improve query understanding, and extract user intent and context to deliver accurate, relevant, and personalized results for users.
  • Prototype, optimize, and productionize ML models that help deliver key results.
  • Evaluate performance of search and recommendation systems and models end to end.
  • Influence the company’s ML system and data infrastructure to power personalization, recommendations to make it faster for our users to create communication materials.
  • Collaborate closely with product managers, scientists, full-stack engineers, and designers on product teams.
  • Communicate with business, data, and engineering counterparts to clarify requirements, provide feedback, and share discovered data stories with stats, charts, and formal presentations. Propose recommendations to maximize business impact.

BioRender provides an online platform for creating scientific illustrations tailored for the life sciences sector. Users can access thousands of pre-drawn icons and templates covering over 30 fields, allowing scientists, researchers, and educators to produce professional and visually appealing figures efficiently. The platform's user-friendly interface enables clients, including academic researchers and pharmaceutical companies, to create figures for research papers, presentations, and educational materials with minimal effort. BioRender differentiates itself from competitors by offering a vast library of customizable resources and a subscription-based model that caters to various user needs, including enterprise solutions for larger organizations. The company's goal is to simplify the process of creating high-quality scientific illustrations, making it easier for users to communicate their research effectively.

Company Size

201-500

Company Stage

Series A

Total Funding

$17.2M

Headquarters

Toronto, Canada

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased demand for digital communication boosts need for scientific visualization tools.
  • Growing interest in graphical abstracts enhances research visibility and accessibility.
  • Open-access publishing trend increases demand for high-quality, appealing figures.

What critics are saying

  • AI-driven design tools may reduce demand for BioRender's platform.
  • Increased competition from cheaper visualization platforms could erode market share.
  • Potential IP disputes over pre-drawn icons could lead to legal challenges.

What makes Biorender unique

  • BioRender offers a vast library of customizable icons and templates for scientists.
  • The platform provides a user-friendly interface for creating professional scientific figures.
  • BioRender serves diverse clients, including academia, biotech, and pharmaceutical companies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

4%

2 year growth

4%
PR Newswire
Nov 12th, 2024
Researchers Uncover New Role Of Mutant Proteins In Some Of The Deadliest Cancers

Findings could point to new ways to treat RAS-driven cancers BETHESDA, Md., Nov. 12, 2024 /PRNewswire/ -- Researchers at the National Institutes of Health (NIH) and their collaborators have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their well-known role in signaling at the cell surface. Mutant RAS, they found, helps to kick off a series of events involving the transport of specific nuclear proteins that lead to uncontrolled tumor growth, according to a study published Nov. 11, 2024, in Nature Cancer

PR Newswire
Apr 13th, 2023
Peel Therapeutics Reports Excessive Netosis Induction In Long Covid

Peer-reviewed study offers first description of ongoing NETosis induction in Long COVID; provides insights into pathogenesis and can serve as a surrogate marker for persistent pathology Research emphasizes need to explore neutrophil-targeted therapies in acute and chronic COVID-19SALT LAKE CITY, April 13, 2023 /PRNewswire/ -- Peel Therapeutics, an evolutionary-inspired, clinical-stage biotech company, announced research conducted by the company has been published in The Journal of Thrombosis and Haemostasis. The study, NETosis Induction Reflects COVID-19 Severity and Long COVID: Insights from a Two-Center Patient Cohort Study in Israel, evaluated the ability of blood from Israeli patients with Long COVID to induce neutrophil extracellular traps (NETs) as a marker of ongoing inflammation. NETs are sticky webs of DNA released by activated immunes cells that contribute to immunothrombosis (mini-clots) and fibrosis. Peel scientists also correlated NETosis potential with acute disease severity in COVID-19. The study concluded that NET inhibitors may be a possible treatment approach for COVID-19 and recommended additional research to confirm findings. Peel Therapeutics is developing first-in-class Neutrophil Targeting Peptides (NTPs) – originating from natural NET inhibitors in newborns – to block inflammation leading to immunothrombosis and fibrosis

Labiotech
Aug 24th, 2022
Study Findings Could Lead To New Anti-Cancer Drugs

Cancer cells surround themselves with a cloud of adenosine, thereby inhibiting the immune system (left). Ceritinib stops the formation of adenosine. ATP accumulates and activates immune cells (right). Figure: Laura Schäkel/University of Bonn – created with BioRender.com. German scientists say a drug already approved for other purposes can negate how tumor cells protect themselves from the immune system

WFMZ
Jun 15th, 2020
BioRender launched Graphical Abstract Contest on Jun 15th 20'.

Today BioRender, creator of the first web-based graphical tool for scientists to create publication and presentation-ready figures, announced its inaugural Graphical Abstract Contest, to give scientists a way to promote their research and win prize rewards.

INACTIVE